GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Pharmaceuticals Ltd (GREY:GLXKY) » Definitions » Cash Ratio

GlaxoSmithKline Pharmaceuticals (GlaxoSmithKline Pharmaceuticals) Cash Ratio : 1.22 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is GlaxoSmithKline Pharmaceuticals Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. GlaxoSmithKline Pharmaceuticals's Cash Ratio for the quarter that ended in Mar. 2024 was 1.22.

GlaxoSmithKline Pharmaceuticals has a Cash Ratio of 1.22. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for GlaxoSmithKline Pharmaceuticals's Cash Ratio or its related term are showing as below:

GLXKY' s Cash Ratio Range Over the Past 10 Years
Min: 0.79   Med: 1.22   Max: 3.91
Current: 1.22

During the past 13 years, GlaxoSmithKline Pharmaceuticals's highest Cash Ratio was 3.91. The lowest was 0.79. And the median was 1.22.

GLXKY's Cash Ratio is ranked better than
68.47% of 1034 companies
in the Drug Manufacturers industry
Industry Median: 0.565 vs GLXKY: 1.22

GlaxoSmithKline Pharmaceuticals Cash Ratio Historical Data

The historical data trend for GlaxoSmithKline Pharmaceuticals's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Pharmaceuticals Cash Ratio Chart

GlaxoSmithKline Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.04 0.86 1.71 1.25 1.22

GlaxoSmithKline Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.25 - 1.18 - 1.22

Competitive Comparison of GlaxoSmithKline Pharmaceuticals's Cash Ratio

For the Drug Manufacturers - General subindustry, GlaxoSmithKline Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlaxoSmithKline Pharmaceuticals's Cash Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pharmaceuticals's Cash Ratio distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline Pharmaceuticals's Cash Ratio falls into.



GlaxoSmithKline Pharmaceuticals Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

GlaxoSmithKline Pharmaceuticals's Cash Ratio for the fiscal year that ended in Mar. 2024 is calculated as:

Cash Ratio (A: Mar. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=223.656/183.681
=1.22

GlaxoSmithKline Pharmaceuticals's Cash Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash Ratio (Q: Mar. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=223.656/183.681
=1.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GlaxoSmithKline Pharmaceuticals  (GREY:GLXKY) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


GlaxoSmithKline Pharmaceuticals Cash Ratio Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Pharmaceuticals's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


GlaxoSmithKline Pharmaceuticals (GlaxoSmithKline Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
Dr. Annie Besant Road, GSK House, Worli, Mumbai, MH, IND, 400 030
GlaxoSmithKline Pharmaceuticals Ltd is an India-based subsidiary of GlaxoSmithKline plc. GSK India develops and manufactures medicines, vaccines, and consumer products. Its medicines portfolio includes prescription drugs for conditions that include asthma, infectious diseases, mental health, and digestion, as well as nonprescription nutrition and cosmetic products. Its vaccines product line includes treatments for conditions such as influenza, HPV, hepatitis, and measles. Its consumer healthcare products include Horlicks-brand packaged food and beverage powders among other retail products. The company derives most of its revenue from India.

GlaxoSmithKline Pharmaceuticals (GlaxoSmithKline Pharmaceuticals) Headlines

No Headlines